News & Updates
Filter by Specialty:

‘Triple-G’ obesity drug also targets NAFLD in phase II trial
11 Jul 2023
byAudrey Abella
In a subanalysis of a phase II trial on obesity, retatrutide, a triagonist of GIP*, GLP**, and glucagon receptors, also demonstrated multiple favourable signals for nonalcoholic fatty liver disease (NAFLD).
‘Triple-G’ obesity drug also targets NAFLD in phase II trial
11 Jul 2023
Palliative care for interstitial lung disease more difficult than for lung cancer
11 Jul 2023
Providing palliative care (PC) for patients with interstitial lung disease (ILD) appears more challenging than for those with lung cancer (LC), according to a study. Pulmonary specialists have also cited some ILD-specific barriers in PC.